Docoh
Loading...

BOLT Bolt Biotherapeutics

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach combines an antibody that targets a tumor antigen with an immune stimulant that triggers an innate and adaptive immune response in the tumor microenvironment. These systemically-delivered Boltbody ISACs are designed to target tumor cells for elimination by myeloid cells, which are then activated and recruit the adaptive immune system in the anti-tumor response. This leads to the conversion of immunologically “cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing BDC-2034, a Boltbody ISAC targeting CEA, and a pipeline of other immuno-oncology products.

Company profile

BOLT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 Aug 21
16 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Cash on hand (at last report) 59.87M 59.87M 59.87M
Cash burn (monthly) 12.39M 7.92M (positive/no burn)
Cash used (since last report) 44.11M 28.19M n/a
Cash remaining 15.75M 31.67M n/a
Runway (months of cash) 1.3 4.0 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Feb 21 Randall C Schatzman Common Stock Buy Acquire P No No 20 1,500 30K 1,500
9 Feb 21 Quinn William P. Common Stock Buy Acquire P No No 20 1,200 24K 13,898
9 Feb 21 Edgar Engleman Common Stock Buy Acquire P Yes No 20 24,267 485.34K 275,789
9 Feb 21 Edgar Engleman Common Stock Sell Dispose S Yes No 20 20 400 251,522
9 Feb 21 Edgar Engleman Common Stock Acquire X Yes No 0.07 5,655 395.85 251,542
9 Feb 21 Edgar Engleman Common Stock Conversion Acquire C Yes No 0 47,718 0 245,887
9 Feb 21 Edgar Engleman Common Stock Conversion Acquire C Yes No 0 43,901 0 198,169
9 Feb 21 Edgar Engleman Common Stock Conversion Acquire C Yes No 0 150,802 0 154,268
9 Feb 21 Edgar Engleman Common Stock Buy Acquire P Yes No 20 175,733 3.51M 1,997,216
9 Feb 21 Edgar Engleman Common Stock Sell Dispose S Yes No 20 144 2.88K 1,821,483

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 64 5 +1180.0%
Opened positions 59 5 +1080.0%
Closed positions 0 0
Increased positions 1 0 NEW
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 590.85M 176.78M +234.2%
Total shares 41.38M 15.53M +166.4%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Novo Holdings A/S 4.5M $69.63M 0.0%
Vivo Capital 3.87M $59.85M NEW
Pivotal bioVenture Partners Fund I 3.06M $0 0.0%
Citadel Advisors 2.96M $44.86M +0.6%
FMR 2.84M $43.86M NEW
Sofinnova Investments 2.75M $42.58M NEW
Sofinnova Venture Partners X 2.75M $0 0.0%
Ra Capital Management 2.38M $36.77M NEW
Vivo Capital VIII 2.27M $77.06M 0.0%
Pivotal bioVenture Partners Investment Advisor 1.89M $29.24M NEW
Largest transactions
Shares Bought/sold Change
Vivo Capital 3.87M +3.87M NEW
FMR 2.84M +2.84M NEW
Sofinnova Investments 2.75M +2.75M NEW
Ra Capital Management 2.38M +2.38M NEW
Pivotal bioVenture Partners Investment Advisor 1.89M +1.89M NEW
Rock Springs Capital Management 1.62M +1.62M NEW
Nan Fung 1.17M +1.17M NEW
Holocene Advisors 1.08M +1.08M NEW
Suvretta Capital Management 954.09K +954.09K NEW
BLK Blackrock 941.85K +941.85K NEW

Financial report summary

?
Management Discussion
  • Revenue was nil for the three and six months ended June 30, 2021, and $67,000 and $0.2 million for the three and six months ended June 30, 2020, respectively. Revenue in 2020 was generated from the execution of the Toray Development Agreement in March 2019 and the recognition of revenue over time as we fulfill our performance obligations to Toray. We did not perform any services towards satisfying the performance obligation as defined in the Toray Development Agreement or Genmab Agreement during the first half of 2021. We expect to perform services to further our collaborations with Toray and Genmab in the remainder of 2021.
  • Research and development expenses were $19.7 million and $33.8 million for the three and six months ended June 30, 2021, respectively, and $9.2 million and $16.0 million for three and six months ended June 30, 2020, respectively. The increase of $10.5 million between the comparable three months periods was primarily due to a $5.8 million increase in manufacturing expenses related to BDC-1001 and BDC-2034, a $2.3 million increase in personnel-related expenses due to an increase in headcount, a $1.3 million increase in facility-related expenses, and a $1.1 million increase in clinical trial expenses. The increase of $17.9 million between the comparable six-month periods was primarily due to a $9.6 million increase in manufacturing expenses related to BDC-1001 and BDC-2034, a $4.9 million increase in personnel-related expenses due to increase in headcount, a $2.2 million increase in facility-related expenses, and a $0.7 million increase in clinical trial expenses.
  • General and administrative expenses were $4.1 million and $8.4 million for the three and six months ended June 30, 2021, respectively, and $2.0 million and $4.1 million for three and six months ended June 30, 2020, respectively. The increase of $2.1 million between the comparable three months periods was primarily due to a $1.7 million increase in personnel-related expenses due to increase in and headcount and increase in professional services expenses related to consulting services, legal fees and other professional services. The increase of $4.2 million between the comparable six-month periods was primarily due to a $3.0 million increase in personnel-related expenses due to an increase in headcount and increase in professional services expenses related to accounting services, legal fees and other professional services.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg

Proxies

No filings

Patents

APP
Utility
Immunoconjugate Synthesis Method
16 Sep 21
A method for producing an immunoconjugate, the method comprising combining one or more compounds of Formula I and an antibody of Formula II, wherein Formula II is an antibody with one or more lysine residues, in an aqueous solution buffered at a pH of about 7.5 to about 9 until at least 33 mol % of the one or more compounds of Formula I is conjugated to the antibody of Formula II to provide the immunoconjugate of Formula III, wherein Adj is an adjuvant, Z is —CH2—, —C(O)NH—, —C(O)O—, or —C(O)—, L is a linker, E is an ester, and r is the average number of adjuvants attached to the antibody and is a positive number up to about 8, in a first buffered aqueous solution.
GRANT
Utility
Antibody adjuvant conjugates
7 Sep 21
The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker.
APP
Utility
Immunoconjugates Targeting EGFR
24 Jun 21
The invention provides an immunoconjugate of formula: (I), or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 50, “Adj” is an adjuvant moiety, and “Ab” is an antibody construct that has an antigen binding domain that binds EGFR.
APP
Utility
Immunoconjugates
27 May 21
The invention provides an immunoconjugate comprising (a) an antibody construct comprising (i) an antigen binding domain and (ii) an Fc domain and (b) 1-8 adjuvant cores, wherein each adjuvant core is covalently bonded to the antibody construct via a linker, wherein each adjuvant core comprises a 2-amino nitrogen moiety with a pendant nitrogen atom and a point of attachment of the linker to the adjuvant core, and wherein the distance between the pendant nitrogen atom and the point of attachment of the linker is greater than about 5 Å.
APP
Utility
Thienoazepine Immunoconjugates, and Uses Thereof
6 May 21
The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more thienoazepine derivatives.